Have a personal or library account? Click to login
Dendrimer functionalized folate-targeted gold nanoparticles for luciferase gene silencing in vitro: A proof of principle study Cover

Dendrimer functionalized folate-targeted gold nanoparticles for luciferase gene silencing in vitro: A proof of principle study

Open Access
|Dec 2018

References

  1. 1. Z. Ziraksaz, A. Nomani, M. Soleimani, B. Bakhshandeh, E. Arefian, I. Haririan and M. Tabbakhian, Evaluation of cationic dendrimer and lipid as transfection reagents of short RNAs for stem cell modification, Int. J. Pharm.448 (2013) 231–238; https://doi.org/10.1016/j.ijpharm.2013.03.03510.1016/j.ijpharm.2013.03.035
  2. 2. Y.-C. Tseng, S. Mozumdar and L. Huang, Lipid-based systemic delivery of siRNA, Adv. Drug Deliv. Rev.61 (2009) 721–731; https://doi.org/10.1016/j.addr.2009.03.00310.1016/j.addr.2009.03.003
  3. 3. S. Dorasamy, N. Narainpersad, M. Singh and M. Ariatt, Novel targeted liposomes deliver sirna to hepatocellular carcinoma cells in vitro, Chem. Biol. Drug Des.80 (2012) 647–656; https://doi.org/10.1111/j.1747-0285.2012.01446.x10.1111/j.1747-0285.2012.01446.x
  4. 4. M. Banan and N. Puri, The ins and outs of RNAi in mammalian cells, Curr. Pharm. Biotechnol.5 (2004) 441–450; https://doi.org/10.2174/138920104337664310.2174/1389201043376643
  5. 5. D. J. Gary, N. Puri and Y.-Y. Won, Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery, J. Control. Rel.121 (2007) 64–73; https://doi:10.1016/j.jconrel.2007.05.02110.1016/j.jconrel.2007.05.021
  6. 6. J. Turkevich, P. C. Stevenson and J. Hillier, A study of the nucleation and growth processes in the synthesis of colloidal gold, Discuss. Faraday Soc.11 (1951) 55–75; https://doi:10.1039/DF951110005510.1039/df9511100055
  7. 7. G. G. Lazarus, N. Revaprasadu, J. López-Viota and M. Singh, The electrokinetic characterization of gold nanoparticles, functionalized with cationic functional groups, and its interaction with DNA, Colloids Surf. B.121 (2014) 425–431; https://doi.org/10.1016/j.colsurfb.2014.06.03210.1016/j.colsurfb.2014.06.032
  8. 8. E. C. Wiener, S. Konda, A. Shadron, M. Brechbiel and O. Gansow, Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor, Invest. radiol.32 (1997) 748–754; https://doi.org/10.1097/00004424-199712000-0000510.1097/00004424-199712000-00005
  9. 9. Y. Wang, R. Guo, X. Cao, M. Shen and X. Shi, Encapsulation of 2-methoxyestradiol within multi-functional poly (amidoamine) dendrimers for targeted cancer therapy, Biomaterials32 (2011) 3322–3329; https://doi.org/10.1016/j.biomaterials.2010.12.06010.1016/j.biomaterials.2010.12.060
  10. 10. X. Shi, K. Sun and J. R. Baker Jr, Spontaneous formation of functionalized dendrimer-stabilized gold nanoparticles, J. Phys. Chem. C.112 (2009) 8251–8258; https://doi.org/10.1021/jp801293a10.1021/jp801293a
  11. 11. C. T. de Ilarduya, Y. Sun and N. Düzgüneş, Gene delivery by lipoplexes and polyplexes, Eur. J. Pharm. Sci.40 (2010) 159–170; https://doi.org/10.1016/j.ejps.2010.03.01910.1016/j.ejps.2010.03.019
  12. 12. T. Xiao, X. Cao and X. Shi, Dendrimer-entrapped gold nanoparticles modified with folic acid for targeted gene delivery applications, J. Control. Release172 (2013) e114-e115; https://doi.org/10.1016/j.jconrel.2013.08.27510.1016/j.jconrel.2013.08.275
  13. 13. D. Pan, J. L. Turner and K. L. Wooley. Folic acid-conjugated nanostructured materials designed for cancer cell targeting, Chem. Commun. (2003) 2400–2401; https://doi.org/10.1039/B307878G10.1039/b307878g
  14. 14. G. A. Mansoori, K. S. Brandenburg and A. Shakeri-Zadeh, A comparative study of two folateconjugated gold nanoparticles for cancer nanotechnology applications, Cancers2 (2010) 1911–1928; https://doi.org/10.3390/cancers204191110.3390/cancers2041911
  15. 15. Y. Chang, N. Liu, L. Chen, X. Meng, Y. Liu, Y. Li and J. Wang, Synthesis and characterization of DOX-conjugated dendrimer-modified magnetic iron oxide conjugates for magnetic resonance imaging, targeting, and drug delivery, J. Mater. Chem.22 (2012) 9594–9601; https://doi.org/10.1039/C2JM16792A10.1039/c2jm16792a
  16. 16. S. Honary and F. Zahir, Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 2), Trop. J. Pharm. Res.12 (2013) 265–273; http://dx.doi.org/10.4314/tjpr.v12i2.1910.4314/tjpr.v12i2.19
  17. 17. L. M. Hellman and M. G. Fried, Electrophoretic mobility shift assay (EMSA) for detecting protein–nucleic acid interactions, Nat. Protoc.2 (2007) 1849–1861; https://doi.org/10.1038/nprot.2007.24910.1038/nprot.2007.249
  18. 18. C.-C. Chuang and C.-W. Chang, Complexation of bioreducible cationic polymers with gold nanoparticles for improving stability in serum and application on nonviral gene delivery, ACS Appl. Mater. Inter.7 (2015) 7724–7731; https://doi.org/10.1021/acsami.5b0073210.1021/acsami.5b00732
  19. 19. N. Lewinski, V. Colvin and R. Drezek. Cytotoxicity of nanoparticles, Smal.4 (2008) 26–49; https://doi.org/10.1002/smll.20070059510.1002/smll.200700595
  20. 20. R. Shukla, V. Bansal, M. Chaudhary, A. Basu, R. R. Bhonde and M. Sastry, Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview, Langmuir21 (2005) 10644–10654; https://doi.org/10.1021/la051371210.1021/la0513712
  21. 21. Y. Shan, T. Luo, C. Peng, R. Sheng, A. Cao, X. Cao, M. Shen, R. Guo, H. Tomás and X. Shi, Gene delivery using dendrimer-entrapped gold nanoparticles as nonviral vectors, Biomaterials33 (2012) 3025–3035; https://doi.org/10.1016/j.biomaterials.2011.12.04510.1016/j.biomaterials.2011.12.045
  22. 22. S. H. Lee, K. H. Bae, S. H. Kim, K. R. Lee and T. G. Park, Amine-functionalized gold nanoparticles as non-cytotoxic and efficient intracellular siRNA delivery carriers, Int. J. Pharm.364 (2008) 94–101; https://doi.org/10.1016/j.ijpharm.2008.07.02710.1016/j.ijpharm.2008.07.027
  23. 23. A. Daniels, M. Singh and M. Ariatti, Pegylated and non-pegylated siRNA lipoplexes formulated with cholesteryl cytofectins promote efficient Luciferase knockdown in HeLa tat luc cells, Nucleos. Nucleot. Nucl.32 (2013) 206–220; https://doi.org/10.1080/15257770.2013.77607810.1080/15257770.2013.776078
  24. 24. M. Elsabahy, A. Nazarali and M. Foldvari, Non-viral nucleic acid delivery: key challenges and future directions, Curr. Drug Deliv.8 (2011) 235–244; https://doi.org/10.2174/15672011179525617410.2174/156720111795256174
  25. 25. T. Bettinger, R. C. Carlisle, M. L. Read, M. Ogris and L. W. Seymour, Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells, Nucleic Acids Res.29 (2001) 3882–3891; https://doi.org/10.1093/nar/29.18.388210.1093/nar/29.18.3882
  26. 26. H. Kang, R. DeLong, M. H. Fisher and R. L. Juliano, Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides, Pharm. Res.22 (2005) 2099–2106; https://doi.org/10.1007/s11095-005-8330-510.1007/s11095-005-8330-5
  27. 27. R. B. Kolhatkar, K. M. Kitchens, P. W. Swaan and H. Ghandehari, Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability, Bioconjug. Chem.18 (2007) 2054–2060; https://doi.org/10.1021/bc060388910.1021/bc0603889
  28. 28. B. Weide, S. Pascolo, B. Scheel, E. Derhovanessian, A. Pflugfelder, T. K. Eigentler, G. Pawelec, I. Hoerr, H.-G. Rammensee and C. Garbe, Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients, J. Immunother.32 (2009) 498–507; https://doi.org/10.1097/CJI.0b013e3181a0006810.1097/CJI.0b013e3181a00068
  29. 29. M. L. Patil, M. Zhang, S. Betigeri, O. Taratula, H. He and T. Minko, Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery, Bioconjug. Chem.19 (2008) 1396–1403; https://doi.org/10.1021/bc800072210.1021/bc8000722
  30. 30. S. Zhang, H. Gao and G. Bao, Physical principles of nanoparticle cellular endocytosis, ACS Nano9 (2015) 8655–8671; https://doi.org/10.1021/acsnano.5b0318410.1021/acsnano.5b03184
DOI: https://doi.org/10.2478/acph-2019-0008 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 49 - 61
Accepted on: Sep 9, 2018
|
Published on: Dec 7, 2018
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:

© 2018 Londiwe Simphiwe Mbatha, Fiona Chepkoech Maiyo, Moganavelli Singh, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.